We investigated the reliability of nalidixic acid (NA) susceptibility as a marker of ciprofloxacin susceptibility in Salmonella, analysing 302 stool isolates. NC53 of the MicroScan system was used for NA susceptibility tests and the E-test was used for ciprofloxacin susceptibility tests. Among the isolates, 178 (58.9 %) were serogroup B, 74 (24.5 %) were serogroup D, 27 (8.9 %) were serogroup C and 23 (7.6 %) were from other minor serogroups. Globally, susceptibility to NA correctly predicted the susceptibility of Salmonella to ciprofloxacin, with a sensitivity of 81.5 %, a specificity of 97.6 %, and positive and negative predictive values of 88 and 96 %, respectively. However, there were differences among the serogroups in terms of sensitivity (P<0.001) and positive predictive values (P=0.013). NA is a reliable marker for serogroup D, but not for serogroups B or C. According to these findings, NA susceptibility measured with the MicroScan system can be used as a marker of ciprofloxacin resistance in some serogroups in our setting.
Salmonella is responsible for a wide range of human diseases and is one of the leading causes of food-borne disease in our region [1, 2] . Nontyphoidal Salmonella causes gastroenteritis with self-limiting diarrhoea, cramping and acute fever [3] , and is the second most frequently isolated bacteria from diarrhoea faeces after Campylobacter. The high incidence of nontyphoidal salmonellosis has considerable economic impact, and the total annual cost of the disease is estimated to be $4.4 billion in the USA alone [4] . There is a need for more economical methods to detect the infection and perform antibiotic susceptibility tests for identified strains. In a recent study of stool cultures in our region [5] , 54 (59.3 %) out of 91 isolates of Salmonella enterica belonged to Salmonella serogroup D, which is susceptible to cefotaxime (100 %), ciprofloxacin (55.6 %), ampicillin (94.3 %) and trimethoprim/sulfamethoxazole (100 %), while 33 (36.3 %) belonged to serogroup B, which is susceptible to cefotaxime (100 %), ciprofloxacin (78.8 %), trimethoprim/sulfamethoxazole (86.9 %) and ampicillin (9.1 %), and 2 (2.2 %) belonged to serogroup C, which is susceptible (100 %) to all of the above antibiotics. Empirical treatment with ciprofloxacin is therefore not valid due to the high resistance rates, and it is recommended that the susceptibility of antibiotics be studied before treatments are selected.
The MicroScan system (Siemens Healthcare Diagnostics, USA) is widely used to evaluate antibiotic susceptibility, but most of the susceptibility panels in this system cannot detect ciprofloxacin susceptibility; therefore, the minimum inhibitory concentration (MIC) must be established separately with an E-test, increasing the expenditure and diagnostic delay. Our hypothesis was that nalidixic acid (NA) susceptibility, determined using the MicroScan system, could be used as a surrogate test when a ciprofloxacin MIC test is not possible, avoiding this additional step. The objective of this study was to determine the predictive capacity of NA susceptibility as a marker of ciprofloxacin susceptibility in our setting.
A total of 302 stool isolates of Salmonella spp. were analysed in the microbiology laboratory of the Virgen de las Nieves University Hospital in Granada (Spain) from 2012 through 2016. The stool samples were from paediatric and adult patients (age 0-86 years old) from the Emergency, Paediatrics and Digestive departments. All isolates underwent NA and ciprofloxacin susceptibility tests. Salmonella isolates were identified and grouped as previously reported [6] , with serogroups being determined by slide agglutination using specific antisera. Because phase 1 or phase 2 flagellar antigens were not studied, serotypes were not considered. Panel NC53 of the MicroScan system was used to determine NA susceptibility and the E-test (Liofilchem, Roseto degli Abruzzi, Italy) was used to determine ciprofloxacin susceptibility. The MIC breakpoints selected for reduced susceptibility were >0.125 µg ml À1 for ciprofloxacin and >16 µg ml À1 for NA, based on previous studies [7] . We performed Fisher's exact test to compare sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) among the serogroups [8] .
Out of the 302 isolates of Salmonella spp., 178 (58.9 %) were serogroup B, 74 (24.5 %) were serogroup D, 27 (8.9 %) were serogroup C and 23 (7.6 %) were from other minor serogroups. Table 1 presents the ciprofloxacin and NA susceptibility test results for the different isolates. Statistically significant differences were found among the serogroups in terms of sensitivity (P<0.001) and PPV (P=0.013).
Various studies have described a correlation between NA resistance and ciprofloxacin resistance in Salmonella spp. [9] [10] [11] [12] . The performance of NA as a ciprofloxacin resistance marker has been widely reviewed in S. enterica var. Typhi [13, 14] , but little studied in other serovars. Overall, susceptibility to NA accurately predicted the susceptibility of Salmonella to ciprofloxacin in the present study. Our global result is consistent with previous findings indicating that the identification of NA resistance had a sensitivity of 100 % and specificity of 87.3 % to detect isolates for which the ciprofloxacin MIC was !0.125 µg ml À1 [10] . However, the sensitivity for the detection of ciprofloxacin resistance in serogroup B Salmonella was low (40 %) in our study, with a PPV of only 60 %. The majority of our cases were serogroup B, and the fact that only 6 out of 15 (40 %) ciprofloxacin resistances were correctly detected by NA resistance in this serogroup is a major limitation of NA screening in Salmonella species other than S. Typhi. Therefore, NA is not reliable as a surrogate marker to predict ciprofloxacin resistance in serogroup B, but it did achieve a markedly superior PPV for the other serogroups. However, the specificity (97.5 %) and NPV (94.6 %) of NA for the detection of ciprofloxacin resistance in serogroup B remained high, indicating that susceptibility values are more reliable than resistance values. In 2005, Hakanen et al. [15] reported the emergence of cases of the Southeast Asia strain that were susceptible to NA but resistant to ciprofloxacin, in line with the present findings. One possible reason for the reduced sensitivity of NA in serogroup B in our setting may be that this serogroup accumulates other resistance mechanisms that are not detected by the study of susceptibility.
Salmonella serogroup D and other serogroups are much more resistant to fluoroquinolone than serogroups B and C. Thus, NA is a useful marker to predict fluoroquinolone resistance in serogroup D but not serogroups B or C. ciprofloxacin and may serve to detect Salmonella resistance, with no need for the E-test, although it also contains antibiotics that may not be relevant for other bacteria isolated in the microbiology laboratory. The results for MicroScan reliability may vary according to the characteristics of the strains in different regions. In Spain, NA susceptibility tested with the MicroScan system can be used as a ciprofloxacin resistance marker in Salmonella serogroup D. According to the present findings, although no single test detects resistance due to all of the possible ciprofloxacin resistance mechanisms in Salmonella spp., as indicated by the CLSI [7] , NA in MicroScan panels could be used as a marker of ciprofloxacin resistance for some serogroups in our setting. In conclusion, MicroScan panels with NA can be applied with care to predict ciprofloxacin resistance in Salmonella species, with the exception of serogroup B, the most frequent serogroup in our series. 
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